Levosimendan

SKU: orb1305351

Description

Levosimendan (OR1259) is a calcium-sensitizing agent that enhances cardiac contractility by binding to cardiac troponin C, increasing myofilament calcium sensitivity without elevating intracellular calcium levels. It is widely used in cardiovascular research, particularly in studies of heart failure, employing both in vitro assays and in vivo animal models to investigate its inotropic and vasodilatory effects.

Research Area

Cell Biology, Metabolism Research, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 141505-33-1
• MW: 280.28
• Purity: 99.70%
• Formula: C₁₄H₁₂N₆O
• SMILES: C[C@H]1C(C2=CC=C(NN=C(C#N)C#N)C=C2)=NNC(=O)C1
• Target: Potassium Channel,Autophagy,Carbonic Anhydrase,PDE
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (7.14 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);DMSO:45 mg/mL (160.55 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• In Vivo:
  Levosimendan caused contraction and relaxation of failing human cardiomyocytes, with a mean maximum increase in twitch tension of 47% at 0.8 μM Levosimendan.Levosimendan induced a rapid dose-dependent increase in hemodynamic functions in patients with compensated heart failure.Levosimendan caused a significant hyperpolarization (EPS) of resting potential (EPS) in rat mesenteric artery myocytes. The resting potential of rat mesenteric artery myocytes was markedly hyperpolarized by Levosimendan (EC50: 2.9 μM), with a maximal effect at 10 μM (19.5 mV), which may be produced by activation of glibenclamide-sensitive K+ channels.Levosimendan (3 μM) reduced the Ca50 from 2.73 μM to 1.19 μM.
• In Vitro:
  Levosimendan caused contraction and relaxation of failing human cardiomyocytes, with a mean maximum increase in twitch tension of 47% at 0.8 μM Levosimendan.Levosimendan induced a rapid dose-dependent increase in hemodynamic functions in patients with compensated heart failure.Levosimendan caused a significant hyperpolarization (EPS) of resting potential (EPS) in rat mesenteric artery myocytes. The resting potential of rat mesenteric artery myocytes was markedly hyperpolarized by Levosimendan (EC50: 2.9 μM), with a maximal effect at 10 μM (19.5 mV), which may be produced by activation of glibenclamide-sensitive K+ channels.Levosimendan (3 μM) reduced the Ca50 from 2.73 μM to 1.19 μM.

Storage & Handling

• Storage: keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

OR1855, OR-1855, OR 1259, OR 1855, OR1259, OR-1259, KcsA, inhibit, Inhibitor, Levosimendan, Autophagy, Carbonic Anhydrase, CarbonicAnhydrase, Cardiac troponin C, Simsndan, phosphodiesterase, Phosphodiesterase (PDE), PotassiumChannel, Potassium Channel

Compound Identifiers

PubChem CID

3033825